ArticleEuropean journal of nuclear medicine and molecular imaging2026
[
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05255926 (An Exploratory, Open-Label, Single Center Study of CXCR4-targeted PET/CT Imaging for Evaluation of Hematological Malignancies), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Exploratory, Open-Label, Single Center Study of CXCR4-targeted PET/CT Imaging for Evaluation of Hematological Malignancies
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeThis study aimed to assess and compare the Durie-Salmon PLUS staging performance and high-risk prediction capabilities between [68Ga]Ga-Pentixafor and [18F]FDG PET/CT in newly diagnosed multiple myeloma (NDMM).
methodsEligible participants with NDMM who underwent [68Ga]Ga-Pentixafor and [18F]FDG PET/CT between October 2021 and March 2025 were prospectively enrolled in this study (NCT05255926). The diagnostic and staging performance of [68Ga]Ga-Pentixafor and [18F]FDG were assessed and compared. The parameters including standardized uptake value (SUV), tumor-to-liver ratio (TLR), total bone marrow uptake (TBMU), total bone marrow uptake volume (TBMV), and total burden score (TBS) were calculated. Independent predictors for high-risk NDMM were identified using single-factor and multivariate logistic regression.
resultsSixty-nine participants (40 men) with a median age of 64 years (interquartile range [IQR], 57–71.5 years) were finally analysed. [68Ga]Ga-Pentixafor PET/CT exhibited a higher positive detection rate (82.6% [57/69] vs. 53.6% [37/69], P < 0.001), maximum SUV (SUVmax; 13.5 vs. 5.3 P < 0.001), mean SUV (SUVmean; 3.5 vs. 2.9, P = 0.029), TLR (8.1 vs. 2.0, P < 0.001), and TBS (45 vs. 4, P < 0.001) than [18F]FDG. [68Ga]Ga-Pentixafor-derived TBSCXCR4, TBMVCXCR4, and TBMUCXCR4 positively correlated with bone marrow plasma cell percentage, β2-microglobulin, and total additive score, respectively. For Durie-Salmon PLUS staging, [68Ga]Ga-Pentixafor better identified advanced participants than did [18F]FDG PET/CT (53 vs. 35; P < 0.001). According to the Mayo mSMART 4.0 stratification system, multivariate logistic regression analysis demonstrated that SUVmeanCXCR4 (odds ratio [OR] = 1.752, 95% confidence interval [CI] = 1.085– 2.828, P = 0.022) and TBSCXCR4 (OR = 1.041, 95% CI = 1.011–1.072, P = 0.008) were independent indicators for predicting high-risk NDMM.
conclusionIn NDMM, [68Ga]Ga-Pentixafor demonstrated better diagnostic accuracy, Durie-Salmon PLUS staging, and high-risk prediction capabilities than did [18F]FDG PET/CT. [68Ga]Ga-Pentixafor-derived SUVmeanCXCR4 and TBSCXCR4 could accurately identify high-risk NDMM. Trial registration number: NCT05255926.
Indexed as
Identifiers
41760826What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.